Literature DB >> 14558185

Benefit-risk analysis: a proposal using quantitative methods.

William L Holden1, Juhaeri Juhaeri, Wanju Dai.   

Abstract

This is the first part of a two-article series which will introduce the theory and practice of a proposed set of quantitative methods for benefit-risk analysis. Adjustments to number-needed-to-treat (NNT) analysis and a new method, minimum clinical efficacy (MCE) analysis are presented and critically discussed. The goal of these methods is to condense into a summary metric the benefit-risk profile of a product so that manufacturers, regulators, clinicians and patients can better understand and participate in risk management. A second article will present examples of these methods.

Entities:  

Mesh:

Year:  2003        PMID: 14558185     DOI: 10.1002/pds.887

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  11 in total

Review 1.  The precautionary principle and pharmaceutical risk management.

Authors:  Torbjörn Callréus
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  A model for decision support in signal triage.

Authors:  Bennett Levitan; Chuen L Yee; Leo Russo; Richard Bayney; Adrian P Thomas; Stephen L Klincewicz
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 3.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

Review 4.  Kidney cancer: Recurrence in renal cell carcinoma: the work is not done.

Authors:  Maxine Sun; Toni K Choueiri
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

5.  Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care.

Authors:  Richard Feinn; Brenda Curtis; Henry R Kranzler
Journal:  J Clin Psychiatry       Date:  2016-03       Impact factor: 4.384

6.  Sex differences in the effectiveness of statins after myocardial infarction.

Authors:  Igor Karp; Shun-Fu Chen; Louise Pilote
Journal:  CMAJ       Date:  2007-01-30       Impact factor: 8.262

7.  Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability.

Authors:  Eric D Shah; Corey A Siegel; Kelly Chong; Gil Y Melmed
Journal:  Dig Dis Sci       Date:  2015-03-14       Impact factor: 3.199

Review 8.  A framework for organizing and selecting quantitative approaches for benefit-harm assessment.

Authors:  Milo A Puhan; Sonal Singh; Carlos O Weiss; Ravi Varadhan; Cynthia M Boyd
Journal:  BMC Med Res Methodol       Date:  2012-11-19       Impact factor: 4.615

Review 9.  Assessing the benefit: risk ratio of a drug--randomized and naturalistic evidence.

Authors:  François Curtin; Pierre Schulz
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

10.  Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis.

Authors:  Alejandro Lazo-Langner; Marc A Rodger; Nicholas J Barrowman; Tim Ramsay; Philip S Wells; Douglas A Coyle
Journal:  BMC Med Res Methodol       Date:  2012-01-10       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.